Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lantheus Holdings, Inc.LNTH · Entity 690 | Chief Medical Officer | March 05, 2024 | March 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lantheus Holdings, Inc.
Report date March 05, 2024 · Filed March 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Theranostics Consulting SAS | 38,841 |
Reported balance
After 2024-03-05 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-03-05 · Tax withholding · Disposed 546 · Balance 38,841 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2024 Filed Mar 7, 2024 21:30 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | Tax withholdingCommon Stock | 546 | $65.36 | $35,686.56 |
DisclosureSEC source: 0000950170-24-028033 · ownership.xml · nonDerivative · entry 1 Provost Jean-Claude · CIK 0001960060 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Theranostics Consulting SAS Disclosed balance after: 38,841 Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:20 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 10,998 | $0.00 Strike: $64.64 | $0.00 |
DisclosureSEC source: 0000950170-24-026662 · ownership.xml · derivative · entry 2 Provost Jean-Claude · CIK 0001960060 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Theranostics Consulting SAS Disclosed balance after: 10,998 Underlying: Common Stock · 10,998 shares Expires 2034-03-01 F2 · derivative.exercise_date: The option vests in three equal annual installments beginning on March 1, 2025. Read SEC document |
| March 01, 2024 Filed Mar 6, 2024 01:20 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 18,564 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-026662 · ownership.xml · nonDerivative · entry 1 Provost Jean-Claude · CIK 0001960060 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · By Theranostics Consulting SAS Disclosed balance after: 39,387 F1 · kind: Consists of 6,188 restricted stock units that vest in equal installments over a three-year period and 12,376 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 02:11 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantStock Option (right to buy) · Derivative | 9,535 | $0.00 Strike: $73.35 | $0.00 |
DisclosureSEC source: 0000899243-23-007265 · doc4.xml · derivative · entry 2 Provost Jean-Claude · CIK 0001960060 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Theranostics Consulting SAS Disclosed balance after: 9,535 Underlying: Common Stock · 9,535 shares Expires 2033-03-02 F2 · shares: The reporting person is the managing partner of the company that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. F3 · derivative.exercise_date: The option vests in three equal annual installments beginning on March 2, 2024. Read SEC document |
| March 02, 2023 Filed Mar 7, 2023 02:11 UTC | Lantheus Holdings, Inc. LNTH · Entity 690 | GrantCommon Stock | 16,359 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-007265 · doc4.xml · nonDerivative · entry 1 Provost Jean-Claude · CIK 0001960060 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Theranostics Consulting SAS Disclosed balance after: 20,823 F1 · kind: Consists of 5,453 restricted stock units that vest in equal installments over a three-year period and 10,906 Total Shareholder Return performance-based restricted stock units ("PSUs") that cliff vest following a three-year performance period. The amount of PSUs included in this Report reflects the target award, however the ultimate award size can range from 0% to 200% of the target based on the actual performance achieved at the end of the performance period. F2 · shares: The reporting person is the managing partner of the company that owns the reported securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.